In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"HEALTH ECONOMICS DEVELOPMENT PLAN" EARLY IN DEVELOPMENT PROCESS RECOMMENDED BY PAREXEL EXEC; GLOBAL QoL SCALES NOT SUFFICIENT FOR CLAIMS -- FDAer MORRIS

Executive Summary

Drug companies should construct a "complete health economics development plan" as early as possible in the drug development process, Parexel/S&FA Senior VP Peter Malamis advised at an Institute for International Research meeting May 19 in Washington, D.C.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel